Aclaris Therapeutics’ monoclonal antibody (mAb) failed to show benefit in a Phase II atopic dermatitis (AD) trial.
The ADMIRATION trial (NCT07011706) of bosakitug, a humanised anti-thymic stromal lymphopoietin (TSLP) mAb, did not achieve the primary or secondary endpoints; however, pharmacodynamic (PD) results showed “robust target engagement” of TSLP and downregulation of biomarkers related to immune activation, including Th1, Th2, and Th17.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company added that bosakitug was generally well tolerated in this trial.
Dr Neal Walker, CEO of Aclaris, said: “We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone. We are grateful to the patients and investigators whose participation and commitment made this study possible.
“These results do not change our development priorities, which remain focused on our oral kinase inhibitors and anti-TSLP/IL-4Rα bispecific antibody ATI-052.”
Walker said this includes the initiation of a Phase IIb trial of its oral ITK/JAK3 inhibitor modzatinib in lichen planus, and a Phase IIb trial with ATI-052 in eosinophilic esophagitis, with the latter expected in the first quarter of 2027.
The company has also completed investigational new drug (IND)-enabling studies for oral ITK inhibitor ATI-9494.
Aclaris gained marketing authorisation for the development, manufacturing and commercialisation of bosakitug from its owner, Biosion, in November 2024. Aclaris has the rights for the drug in all regions outside of Greater China.
The AD market, also known as eczema, is fierce, with major blockbusters such as Sanofi’s Dupixent (dupilumab) and AbbVie’s Rinvoq (upadacitinib) dominating the landscape. As Sanofi’s therapy will soon see patent expiries, the company is already prepared with a successor, amlitelimab, which was successful in a Phase III trial as per data unveiled in January 2026, and the company is seeking regulatory approval.
Nektar Therapeutics is further behind but has hopes for its therapy rezpeg (rezpegaldesleukin) in AD, which demonstrated potential across monthly and quarterly maintenance dosing regimens during a Phase II trial. This potential for quarterly dosing could be notable for uptake, key opinion leaders (KOLs) said.
A GlobalData report predicts that across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), the AD market was worth $8.5bn in 2023 and is set to reach $21.5bn by 2033, at a CAGR of 9.8%.
GlobalData is the parent company of Clinical Trials Arena.
